当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
FIBRYNA; FIBRYGA, Fibrinogen (Human)
申请企业
Octapharma Pharmazeutika Produktionsges.m.b.H.
药品名称
FIBRYNA; FIBRYGA, Fibrinogen (Human)
承诺描述
A prospective observational study of patients =12 years of age with congenital afibrinogenemia and hypofibrinogenemia treated with FIBRYNA for at least 10 major bleeding events to further characterize the risk of thromboembolic events following Fibryna treatment